Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TROFOSFAMIDE for Alveolar rhabdomyosarcoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 12 adverse event reports in the FDA FAERS database where TROFOSFAMIDE was used for Alveolar rhabdomyosarcoma.

Most Reported Side Effects for TROFOSFAMIDE

Side Effect Reports % Deaths Hosp.
Acute myeloid leukaemia 18 16.5% 9 1
Myelodysplastic syndrome 18 16.5% 9 1
Product use in unapproved indication 16 14.7% 0 2
Off label use 15 13.8% 2 1
Neutropenia 14 12.8% 1 6
Anaemia 13 11.9% 0 0
Dyspnoea 12 11.0% 0 7
Oedema 10 9.2% 0 0
Pleural effusion 10 9.2% 0 5
Hepatosplenomegaly 9 8.3% 0 0
Hyperleukocytosis 9 8.3% 1 0
Rhabdomyosarcoma recurrent 9 8.3% 2 0
Thrombocytopenia 9 8.3% 0 0
Neoplasm progression 8 7.3% 2 0
Acute kidney injury 7 6.4% 1 5

Other Indications for TROFOSFAMIDE

Metastatic malignant melanoma (32) Diffuse large b-cell lymphoma (13) Langerhans' cell histiocytosis (11) Angioimmunoblastic t-cell lymphoma (6) Product used for unknown indication (6) Hodgkin's disease (5) Lymphoma (5)

Other Drugs Used for Alveolar rhabdomyosarcoma

VINCRISTINE (181) DACTINOMYCIN (134) CYCLOPHOSPHAMIDE (126) IRINOTECAN (114) IFOSFAMIDE (110) DOXORUBICIN (71) ETOPOSIDE (58) CARBOPLATIN (39) TEMSIROLIMUS (38) VINORELBINE (23)

Related Pages

TROFOSFAMIDE Full Profile All Alveolar rhabdomyosarcoma Drugs TROFOSFAMIDE Demographics TROFOSFAMIDE Timeline